The ruling is a procedural win for Kroger — its claims survive dismissal — but no damages have been quantified and the case is years from resolution. Monitor for summary judgment motions and any settlement discussions. The MDL's scope (scores of drugs, dozens of defendants) means Kroger's ultimate recovery, if any, is highly uncertain and likely years away.
Price Chart
Executive Summary
In the Generic Pharmaceuticals MDL, Judge Rufe partially granted and partially denied Epic Pharma's motions to dismiss antitrust claims. The Kroger Co. is among the eight plaintiffs whose complaints against Epic were found to sufficiently allege a conspiracy to fix prices of Ursodiol — those claims survive. Three other complaints (CVS, HCSC, Molina) were dismissed against Epic for insufficient pleading. For Kroger, the ruling removes near-term dismissal risk and allows the case to proceed toward discovery, but no damages have been awarded and the litigation remains in early stages.
Court Ruling Details
Key Facts
- Kroger's complaint against Epic Pharma for Ursodiol price-fixing conspiracy survives Epic's motion to dismiss
- The court found Kroger's complaint sufficiently alleged parallel conduct, motive, action against self-interest, and traditional conspiracy (meetings/communications between Epic, Lannett, and Actavis)
- Epic raised Ursodiol price >1000% (from $0.45 to $5.10 per 300-mg unit) on May 6, 2014, days after Lannett entered at $5.11
- Three other complaints (CVS, HCSC, Molina) were dismissed against Epic for failing to allege specific Epic conduct
- No damages have been awarded — this is a motion-to-dismiss ruling, not a final judgment
- The ruling is interlocutory; Epic may seek summary judgment after discovery
Financial Impact
No damages awarded or pleaded amount stated in the opinion. The ruling allows Kroger's antitrust claims against Epic to proceed, preserving potential recovery but with no quantified exposure or award at this stage.
Risk Factors
- Epic may move for summary judgment after discovery, potentially narrowing or eliminating claims
- No damages have been awarded or quantified — ultimate recovery is uncertain
- Appeals of interlocutory rulings are not immediately available, but final judgment appeals could take 1-2 additional years
- The MDL has been ongoing since 2016; resolution timeline is extended
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1as9hv5f-KR |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $58.49 $60.00 | ▲ +2.58% | ▲ +2.80% | $59.37 (+1.50%) |
Sep 2, 2026 29d ago | 8-K | $58.51 $58.49 | ▼ −0.03% | ▲ +1.11% | $59.37 (+1.47%) |
Jul 1, 2026 13w ago | 8-K | $56.24 $58.54 | ▲ +4.09% | ▲ +3.83% | $59.37 (+5.57%) |
Jun 26, 2026 13w ago | 8-K | $55.91 $58.25 | ▲ +4.19% | ▲ +2.80% | $59.37 (+6.19%) |
Jun 25, 2026 14w ago | Court Ruling | $57.77 $58.22 | ▲ +0.78% | ▼ −0.65% | $59.37 (+2.77%) |
Jun 18, 2026 15w ago | 8-K | $56.61 $57.77 | ▲ +2.05% | ▲ +3.71% | $59.37 (+4.88%) |
May 27, 2026 18w ago | 8-K | $64.69 $61.22 | ▼ −5.37% | ▼ −5.84% | $59.37 (−8.22%) |
May 19, 2026 19w ago | Court Ruling | $70.62 $64.85 | ▲ +8.17% | ▲ +10.41% | $59.37 (+15.93%) |
May 12, 2026 20w ago | Court Ruling | $64.62 $70.60 | ▲ +9.25% | ▲ +9.86% | $59.37 (−8.12%) |
Apr 29, 2026 22w ago | Court Ruling | $67.09 $66.92 | ▼ −0.25% | ▼ −3.36% | $59.37 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access